Article

Shear stress investigation across mechanical heart valve.

School of Mechanical and Automation Engineering, Shanghai Institute of Technology, Shanghai, China.
ASAIO journal (American Society for Artificial Internal Organs: 1992) (Impact Factor: 1.39). 01/2007; 53(5):530-6. DOI: 10.1097/MAT.0b013e318157c093
Source: PubMed

ABSTRACT The particle image velocimetry technique was used to study the shear field across a transparent mechanical heart valve model in one cardiac cycle. Shear stress was continuously increased until peak systole and high turbulent stress was observed at the orifice of the central channel and also around the occluder trailing tips. The peak Reynolds shear stress was up to 500 N/m at peak systole, which was higher than the normal threshold for hemolysis.

0 Bookmarks
 · 
42 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our group is currently developing a pneumatic ventricular assist device (PVAD). In general, the major causes of hemolysis in a pulsatile VAD are cavitation, and Reynolds shear stress (RSS) in the mechanical heart valve (MHV). In a previous study, we investigated MHV cavitation. To select the optimal bileaflet valve for our PVAD, in the current study, we investigated RSS and viscous shear stress (VSS) downstream of three different types of commercial bileaflet valves by means of 2D particle image velocimetry (PIV). To carry out flow visualization inside the blood pump and near the valve, we designed a model pump with the same configuration as that of our PVAD. Three types of bileaflet valves (i.e., the ATS valve, the St. Jude valve, and the Sorin Bicarbon valve) were mounted at the aortic position of the model pump, and flow was visualized according to the PIV method. The maximum flow velocity and RSS of the Sorin Bicarbon valve were lower than those of the other two bileaflet valves. The maximum VSS was only 1% of the maximum RSS. Thus, the effect of VSS on blood cell trauma was neglected. The Sorin Bicarbon valve exhibited relatively low levels of RSS, and was therefore considered to be the best valve for our PVAD among the three valves tested.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 07/2009; 55(4):348-54. · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lifelong oral anticoagulation (OAC) therapy is required for the prevention of thromboembolic events after implantation of an artificial heart valve. Thromboembolism and anticoagulant-related bleedings account for approximately 75% of all complications experienced by heart valve recipients (2-9% of patients per year). The present study investigated the efficacy of dabigatran, a new direct thrombin inhibitor for oral use, as compared to unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in preventing thrombus formation on mechanical heart valves in vitro. Blood (230 ml) from healthy young male volunteers was anticoagulated either by dabigatran (1 micromol/l), UFH (150 IU), or LMWH (100 IU). Mechanical heart valve prostheses were placed in an in vitro thrombosis tester and exposed to the anticoagulated blood samples under continuous circulation at a rate of 75 beats per minute. In whole blood with no anticoagulant, the apparatus completely clotted in 15-20 minutes. When blood was treated with dabigatran, the mean thrombus weight was 164+/-55 mg, in the UFH group 159+/-69 mg, and in the LMWH group 182+/-82 mg (p-value: 0.704). Electron microscopy showed no significant difference in thrombus formation in any group. Dabigatran was as effective as UFH and LMWH in preventing thrombus formation on mechanical heart valves in our in vitro investigation. Thus, we hypothesize that dabigatran etexilate might potentially be a useful and competitive orally administered alternative to UFH and LMWH for recipients of alloplastic heart valve prostheses.
    Thrombosis Research 09/2010; 126(3):e196-200. · 3.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thromboembolism and bleeding after mechanical heart valve replacement are still unsolved problems, particularly for patients requiring anticoagulative bridging therapy. The aim of this study was to investigate whether rivaroxaban, a new oral selective and direct coagulation factor Xa inhibitor, is as effective as enoxaparin and unfractionated heparin (UFH) in preventing thrombus formation on mechanical heart valves using an in vitro system. Blood from healthy male donors was anticoagulated with either UFH, enoxaparin, rivaroxaban at 300 ng/ml, (n = 10 each), or rivaroxaban at 30 ng/ml (n = 3). Mechanical aortic valve prostheses were placed into the in vitro testing system THIA II and exposed to the anticoagulant blood mixtures at a pulsatile flow for 60 min. Overall thrombus weight, coagulation parameters, and electron microscopic features of thrombus formation on the valve surface were quantified as endpoints. The mean thrombus weights were 163 ± 64 mg for group 1 (UFH), 341 ± 63 mg for the group 2 (enoxaparin), 238 ± 83 mg for group 3 (rivaroxaban 300 ng/ml) and 1.739 ± 16 mg for group 4 (rivaroxaban 30 ng/ml). Whereas high-dosed rivaroxaban showed no significant differences compared to UFH or enoxaparin, low-dosed rivaroxaban generated a massive thrombus generation, thus differing significantly from all other treatment groups regarding the thrombus weight. We hypothesize that high-dose rivaroxaban is a competitive oral available alternative to UFH and LMWH's, that might be a worthwhile alternative for patients in need of anticoagulative bridging therapy. Prospective studies have to evaluate if rivaroxaban might even overcome the limitations of OAC in patients after implantation of artificial heart valves.
    Journal of Thrombosis and Thrombolysis 07/2011; 32(4):417-25. · 1.99 Impact Factor